KTTA Stock Forecast & Price Target

Pasithea Therapeutics is a promising biotechnology company with a strong focus on developing treatments for central nervous system disorders and other diseases. Their pipeline of drugs, including PAS-004, PAS-003, and PAS-001, show potential for targeting various diseases such as neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, and schizophrenia. Recent protocol amendments to their Phase 1/1b trial of PAS-004 in NF1 patients show a constructive, execution-oriented step to de-risk the eventual Part B dose and strengthen the registrational package. The company also has strong regulatory credibility, with three FDA designations for PAS-004, and is executing towards key milestones in 2026.

Pasithea Therapeutics is a biotechnology company with a negative outlook, due to its early stage of development and lack of any approved drugs in the market. Although the recent Rare Disease Designation for PAS-004 by the FDA is a positive de-risking event and introduces significant upside potential, the company's low market cap and high-risk profile make it a risky investment with limited near-term revenue potential. The $150-250 million estimated value of a potential Priority Review Voucher is not enough to change our outlook on this company, and we maintain a cautious stance on Pasithea's stock.